The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|July 7, 2011
Gen-Probe Life Sciences Positions Molecular Genetic and Pharma Services Business for Future Growth
Advertisement
Gen-Probe Incorporated has expanded its footprint in Wythenshawe, Manchester from 11,000 sq ft to 67,000 sq ft. Among other benefits, the expansion of the facility will provide the catalyst for theconsolidation and further development of a suite of outsourced genomic services. Gen-Probe Life Sciences Ltd. will further develop its suite of genomic services aimed specifically at the R&D stage of drug development. These services will provide support to translational research through the discovery, qualification, and validation of biomarkers and IUO assays with the potential for both drug development and companion diagnostic applications.
David Scott, Senior Director, commercial services and Diaclone, said, “We are excited to beimplementing this next stage in the strategic development of our pharma services brand. We believe that the potential to identify and develop both genomic and proteomic assays for biomarkers at an early stage presents a real value proposition to biopharmaceutical companies seeking companion diagnostics.”
As part of this consolidation, Gen-Probe Life Sciences Ltd. has appointed Dr. Bob Holt as MGS manager responsible for the growth and development of the MGS business, and Haroon Allybacus as business development manager for its pre-clinical, clinical, and cGMP drug development services.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5